Switch to: Citations

Add references

You must login to add references.
  1. Should Non-Invasiveness Change Informed Consent Procedures for Prenatal Diagnosis?Zuzana Deans & Ainsley J. Newson - 2011 - Health Care Analysis 19 (2):122-132.
    Empirical evidence suggests that some health professionals believe consent procedures for the emerging technology of non-invasive prenatal diagnosis (NIPD) should become less rigorous than those currently used for invasive prenatal testing. In this paper, we consider the importance of informed consent and informed choice procedures for protecting autonomy in those prenatal tests which will give rise to a definitive result. We consider whether there is anything special about NIPD that could sanction a change to consent procedures for prenatal diagnosis or (...)
    Download  
     
    Export citation  
     
    Bookmark   9 citations  
  • Imperfect informed consent for prenatal screening: Lessons from the Quad screen.M. Constantine, M. Allyse, M. Wall, R. D. Vries & T. Rockwood - 2014 - Clinical Ethics 9 (1):17-27.
    Objective The study evaluated patient informed consent (IC) for the Quad screen and examined differences in IC between test acceptors and test refusers. A multidimensional model of IC was used. Methods Women seeking prenatal care at nine obstetrics clinics in a large Midwestern city completed surveys between February and December 2006. Surveys contained measures for three dimensions of IC: intention, understanding and controlling influence. Results 56.2% of women did not meet criteria for all three of our dimensions of IC and (...)
    Download  
     
    Export citation  
     
    Bookmark   2 citations  
  • A Disability Critique of the New Prenatal Test for Down Syndrome.Chris Kaposy - 2013 - Kennedy Institute of Ethics Journal 23 (4):299-324.
    Sequenom Inc., a developer of medical diagnostic products, recently made their noninvasive test for Down syndrome available for clinical practice.1 The DNA-based test—given the name “MaterniT21”—requires only a simple maternal blood sample as early as 10 weeks of gestation. In recent clinical trials involving thousands of pregnant women, the MaterniT21 test identified 99.1% of cases of Down syndrome, and gave the correct result in 99.9% of cases when the fetus did not have Down syndrome. Sequenom’s test is thought to be (...)
    Download  
     
    Export citation  
     
    Bookmark   10 citations